JOURNAL ARTICLE

Astra Signs Obesity Deal in China Worth Up to $18.5 Billion.

  • Published In: Bloomberg.com, 2026. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Furlong, Ashleigh; Kresge, Naomi; Tong, Amber 3 of 3

Abstract

The article focuses on AstraZeneca Plc's agreement to pay up to $18.5 billion to CSPC Pharmaceutical Group Ltd. for obesity drug candidates, marking AstraZeneca's entry into the expanding weight-loss market. The deal includes an initial payment of $1.2 billion for eight drug candidates, including four injectable therapies aimed at treating obesity and related conditions. AstraZeneca aims to develop more convenient weight-loss medications that require less frequent dosing, addressing adherence issues seen with current therapies. Additionally, the agreement grants AstraZeneca rights to CSPC's advanced compound SYH2082, which is set to enter human trials. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2026/01, pN.PAG
  • Document Type:Article
  • Subject Area:Business and Management
  • Publication Date:2026
  • Accession Number:191273538
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.